Drugs / 3, 4-Methylenedioxymethamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05219175 | Apr 2024 → Apr 2027 expected | opiate dependence, post-traumatic stress disorder | University of New Mexico | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3, 4-Methylenedioxymethamphetamine | “MDMA (3, 4-Methylenedioxymethamphetamine) has received breakthrough drug status from the FDA for the treatment of PTSD.” NCT05219175 ↗ |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05219175 ↗ |